Floatz logo

AUTOLOGOUS PBL

Renal Cancer

National Cancer Institute (NCI)Cell therapyPhase 1/2Dormant
D
26/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
11/ 100
Competitive Position
81/ 100

Competitive context

298 Active assets in the Renal Cancer cohort.

Asset / SponsorPhaseRating
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

AUTOLOGOUS PBL is also rated in:

metastatic melanomaDormant
D
Indicative ·
30 / 100
View asset →
Stage III MelanomaDormant
D
Indicative ·
30 / 100
View asset →
cutaneous melanomaDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →